Misplaced Pages

Edoxaban: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 03:07, 1 July 2011 editPeryeat (talk | contribs)Extended confirmed users2,689 editsNo edit summary← Previous edit Revision as of 06:49, 1 July 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (repNext edit →
Line 1: Line 1:
{{drugbox {{drugbox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|changed|FDA}}
| UNII = NDU3J18APO | UNII = NDU3J18APO
| verifiedrevid = 401316371 | verifiedrevid = 415900881
| IUPAC_name = ''N'''-(5-chloropyridin-2-yl)-''N''-thiazolopyridine-2-carbonyl)amino]cyclohexyl]oxamide | IUPAC_name = ''N'''-(5-chloropyridin-2-yl)-''N''-thiazolopyridine-2-carbonyl)amino]cyclohexyl]oxamide
| image = Edoxaban_skeletal.svg | image = Edoxaban_skeletal.svg

Revision as of 06:49, 1 July 2011

Pharmaceutical compound
Edoxaban
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • N'-(5-chloropyridin-2-yl)-N-thiazolopyridine-2-carbonyl)amino]cyclohexyl]oxamide
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H30ClN7O4S
Molar mass548.056 g/mol g·mol
  (what is this?)  (verify)

Edoxaban (INN, codenamed DU-176b) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. In animal studies, edoxaban is potent, selective for factor Xa and has good oral bioavailability, but it has not been approved for use in humans.

Several Phase II clinical trials have been conducted, for example for thromboprophylaxis after total hip replacement (phase III early results compare well to enoxaparin), and for stroke prevention in patients with atrial fibrillation (phase III has completed enrollment).

References

  1. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008). "DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles". Journal of Thrombosis and Haemostasis : JTH. 6 (9): 1542–9. doi:10.1111/j.1538-7836.2008.03064.x. PMID 18624979. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. Sobieraj-Teague M, O'Donnell M, Eikelboom J (2009). "New anticoagulants for atrial fibrillation". Seminars in Thrombosis and Hemostasis. 35 (5): 515–24. doi:10.1055/s-0029-1234147. PMID 19739042. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. PMID 20589317
  4. ^ "Phase III Trial Finds Edoxaban Outclasses Enoxaparin in Preventing Venous Thromboembolic Events". 8 Dec 2010.
  5. PMID 20694273
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Antiplatelet drugs
Glycoprotein IIb/IIIa inhibitors
ADP receptor/P2Y12 inhibitors
Prostaglandin analogue (PGI2)
COX inhibitors
Thromboxane inhibitors
Phosphodiesterase inhibitors
Other
Anticoagulants
Vitamin K antagonists
(inhibit II, VII, IX, X)
Factor Xa inhibitors
(with some II inhibition)
Heparin group/
glycosaminoglycans/
(bind antithrombin)
Direct Xa inhibitors ("xabans")
Direct thrombin (IIa) inhibitors
Other
Thrombolytic drugs/
fibrinolytics
Non-medicinal
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories: